SCM
BLRX

Sio Capital Management’s BioLineRX BLRX Stock Holding History

Sio Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-68,544
Closed -$7.65M – 76
2021
Q1 		$7.65M Buy
+68,544
New +$8.24M 1.55% 21

Other funds holding BLRX

PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return

Sio Capital Management's BLRX Position: Q2 2021 in Review

Sio Capital Management sold out of BioLineRX (BLRX) in Q2 2021, closing a stake of 68,544 shares — an estimated $7.65M sold.

Sio Capital Management first reported a position in BLRX in Q1 2021 and held it in 1 quarter. The position peaked at $7.65M in Q1 2021. 28 funds tracked by Wall St. Rank hold BLRX as of Q2 2021.

  • Sio Capital Management reported no remaining BioLineRX position as of Q2 2021 after selling out during the quarter.
  • Sio Capital Management sold 68,544 BioLineRX shares in Q2 2021, an estimated $7.65M.
  • Sio Capital Management first reported a position in BioLineRX in Q1 2021 and held it in 1 quarter.
  • Sio Capital Management's BioLineRX position peaked at $7.65M in Q1 2021.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q2 2021.

Based on Sio Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.